Developer docs
API playgroundTry for free, no card

Search company profiles

deepCDR Biologics

Full company profile

uuid0005qcd

Namestring
deepCDR Biologics
Legal namestring
Alloy Therapeutics, Inc.
Websiteurl
deepcdr.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

deepCDR Biologics is a privately held biotechnology company founded in 2019 and headquartered in Basel, Switzerland. The company self-describes as a provider of 'cutting-edge technologies and services, offering scalable solutions,' but the input data does not specify the therapeutic area, modality, or technical platform. Its public profile is limited, with a headcount of 1–10 employees and a corporate website at deepcdr.com. The founding team comprises Sai Reddy (co-founder & chairman), Cedric Weber (Co-Founder & Director of Technology), Derek Mason, and Simon Friedensohn. No management team beyond the founders is disclosed, and no named products, services lines, scientific publications, patents, or partnerships are reflected in the available data. The same data set contains detailed records for Alloy Therapeutics (a separate U.S.-based transgenic antibody discovery platform), but those products, customers, and platforms cannot be attributed to deepCDR Biologics in this analysis.

Financially, deepCDR Biologics appears to be at a very early stage. Its only documented capital sources are two Venture Kick seed grants totaling approximately $82,382, awarded in January 2020 (the first roughly $41,096 led by Venture Kick and the second roughly $41,286 also from Venture Kick). There is no information on institutional venture funding, revenue, customers, pricing, or contracts. Given the minimal footprint, the company is most plausibly positioned as a pre-revenue research or technology-development entity, with go-to-market, revenue model, and customer segments effectively unspecified in the available evidence. The dominant data gap is the complete absence of post-2020 commercial, hiring, or funding activity.

Short descriptiontext

deepCDR Biologics is a Basel-based, privately held biotechnology company founded in 2019, operating with 1–10 employees to provide what it describes as cutting-edge, scalable biotechnology technologies and services, with no commercialized product or disclosed customer base in the available evidence.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBasel, Switzerland
HQ citystring
Basel
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biologics development services, biotechnology research, bioprocess solutions, therapeutic development, biotech contract services
Industry1 code
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biotechnology Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Platform Licensing (ATX-GX™)
TypeLicensing Royalties
Description

Licensing of proprietary transgenic mouse platforms to pharmaceutical and biotech partners, enabling access to foundational biologics discovery technologies with flexible business terms.

alloytx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1ATX-GX™
Description

Licensed transgenic platform for human antibody discovery with flexible business terms

alloytx.com
Core offering1 text field

deepCDR Biologics is a Basel-based biotechnology company founded in 2019 that provides cutting-edge biotechnology technologies and services with scalable solutions. The company focuses on serving the biologics development needs of pharmaceutical and biotechnology clients with offerings positioned as scalable, technology-driven services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 200+ partners utilizing the platform globally
+2 more records
Product overview1 text field

Alloy Therapeutics is a biotechnology company offering a comprehensive platform of antibody discovery services and related biologics technologies. The core offerings include the ATX-GX™ transgenic mouse platform for fully human antibody discovery, monoclonal and bispecific antibody discovery services, and antibody optimization workflows. These are supported by proprietary AI/ML tools (Alloy Insights) for clone selection and in silico design. The portfolio extends to TCR Mimics, Genetic Medicines, and Cell Therapies, providing an integrated ecosystem for drug discovery from target identification through lead optimization.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic collaboration to advance next-generation antibody discovery. The partnership combines Institute for Protein Innovation's protein science expertise with Alloy Therapeutics' antibody discovery platforms to accelerate therapeutic development.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

GenScript ProBio offers antibody discovery, engineering and biomanufacturing services — a broad incumbent comparable on customer segment and end-to-end biologics service offering.

TypeDirect peer
Description

Alloy Therapeutics operates a transgenic antibody discovery platform (ATX-GX™) with AI/ML-driven clone selection and bispecific engineering capabilities — the same product/customer category (biopharma antibody discovery services) deepCDR Biologics addresses, but at significantly greater scale (200+ partners, 20+ partner INDs).

TypeDirect peer
Description

AbCellera is a publicly listed antibody discovery platform using AI/ML and high-throughput single-cell screening to discover therapeutic antibodies — directly comparable technology/market overlap with deepCDR's stated 'cutting-edge' antibody focus.

TypeDirect peer
Description

Adimab offers a proprietary antibody discovery and optimization platform via partnership-based licensing to pharma and biotech — a direct business-model and offering analogue in the antibody engineering services space.

5Distributed Bio (Charles River Laboratories)
TypeBroad incumbent
Description

Distributed Bio's antibody discovery platform (TAb platform, SuperHuman library) is now part of Charles River Laboratories — a broad incumbent offering antibody discovery services as part of a wider CRO portfolio, directly comparable on customer base and offering.

TypeBroad incumbent
Description

WuXi Biologics provides end-to-end biologics discovery, development and manufacturing services including antibody discovery platforms — a broad incumbent that any antibody-discovery services company competes against for biopharma R&D outsourcing budgets.

TypeEmerging player
Description

Biolojic Design applies AI/ML-driven computational design to antibody engineering — an early-stage, niche AI-native antibody player comparable to the deepCDR positioning around machine-learning-driven CDR engineering.

TypeBroad incumbent
Description

Ablexis's AlivaMab transgenic mouse antibody platform was acquired by AstraZeneca — a relevant comparable on the transgenic antibody discovery platform side, although now embedded inside a major pharma R&D organization.

TypeEmerging player
Description

Specifica built an antibody discovery platform using in vitro display and proprietary libraries before being acquired by AstraZeneca — comparable to deepCDR as an early-stage antibody platform that ultimately required a large-pharma acquirer to commercialize.

10Harbour BioMed
TypeRegional player
Description

Harbour BioMed operates a transgenic mouse (Harbour Mice®) antibody discovery platform — directly comparable platform technology; though based in Asia/global rather than Switzerland, it targets the same biopharma antibody-discovery licensing customer segment.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights3 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

deepCDR Biologics

Biotechnology Servicesdeepcdr.com

deepCDR Biologics is a Basel-based, privately held biotechnology company founded in 2019, operating with 1–10 employees to provide what it describes as cutting-edge, scalable biotechnology technologies and services, with no commercialized product or disclosed customer base in the available evidence.

What deepCDR Biologics does

deepCDR Biologics is a privately held biotechnology company founded in 2019 and headquartered in Basel, Switzerland. The company self-describes as a provider of 'cutting-edge technologies and services, offering scalable solutions,' but the input data does not specify the therapeutic area, modality, or technical platform. Its public profile is limited, with a headcount of 1–10 employees and a corporate website at deepcdr.com. The founding team comprises Sai Reddy (co-founder & chairman), Cedric Weber (Co-Founder & Director of Technology), Derek Mason, and Simon Friedensohn. No management team beyond the founders is disclosed, and no named products, services lines, scientific publications, patents, or partnerships are reflected in the available data. The same data set contains detailed records for Alloy Therapeutics (a separate U.S.-based transgenic antibody discovery platform), but those products, customers, and platforms cannot be attributed to deepCDR Biologics in this analysis.

Financially, deepCDR Biologics appears to be at a very early stage. Its only documented capital sources are two Venture Kick seed grants totaling approximately $82,382, awarded in January 2020 (the first roughly $41,096 led by Venture Kick and the second roughly $41,286 also from Venture Kick). There is no information on institutional venture funding, revenue, customers, pricing, or contracts. Given the minimal footprint, the company is most plausibly positioned as a pre-revenue research or technology-development entity, with go-to-market, revenue model, and customer segments effectively unspecified in the available evidence. The dominant data gap is the complete absence of post-2020 commercial, hiring, or funding activity.

deepCDR Biologics firmographics

Firmographics
Name
deepCDR Biologics
Legal name
Alloy Therapeutics, Inc.
Website
https://deepcdr.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
deepCDR Biologics is a Basel-based, privately held biotechnology company founded in 2019, operating with 1–10 employees to provide what it describes as cutting-edge, scalable biotechnology technologies and services, with no commercialized product or disclosed customer base in the available evidence.
Ownership category
akta.pro rank

deepCDR Biologics industry classification

Industry
Product category
Biotechnology Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Biologics development services
  • Biotechnology research
  • Bioprocess solutions
  • Therapeutic development
  • Biotech contract services

Where deepCDR Biologics is headquartered

Location

Headquarters

HQ city
Basel
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

deepCDR Biologics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Revenue model

  1. Platform Licensing (ATX-GX™): Licensing of proprietary transgenic mouse platforms to pharmaceutical and biotech partners, enabling access to foundational biologics discovery technologies with flexible business terms.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

deepCDR Biologics product offering

Product offering

Core offering

deepCDR Biologics is a Basel-based biotechnology company founded in 2019 that provides cutting-edge biotechnology technologies and services with scalable solutions. The company focuses on serving the biologics development needs of pharmaceutical and biotechnology clients with offerings positioned as scalable, technology-driven services.

Product overview

Alloy Therapeutics is a biotechnology company offering a comprehensive platform of antibody discovery services and related biologics technologies. The core offerings include the ATX-GX™ transgenic mouse platform for fully human antibody discovery, monoclonal and bispecific antibody discovery services, and antibody optimization workflows. These are supported by proprietary AI/ML tools (Alloy Insights) for clone selection and in silico design. The portfolio extends to TCR Mimics, Genetic Medicines, and Cell Therapies, providing an integrated ecosystem for drug discovery from target identification through lead optimization.

Differentiator

Problem solved

Functional benefit

Brands

  • ATX-GX™: Licensed transgenic platform for human antibody discovery with flexible business terms

Quantifiable outcome

  • 200+ partners utilizing the platform globally
  • +2 more outcomes

Companies that use deepCDR Biologics

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

deepCDR Biologics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

deepCDR Biologics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Institute for Protein InnovationcoreStrategic or Co-development PartnerStrategic collaboration to advance next-generation antibody discovery. The partnership combines Institute for Protein Innovation's protein science expertise with Alloy Therapeutics' antibody discovery platforms to accelerate therapeutic development.

Scale indicators3 records

Recent moves3 records

Expansion highlights2 records

deepCDR Biologics competitors and assessment

Company assessment

Broad incumbents

  • GenScript ProBio: GenScript ProBio offers antibody discovery, engineering and biomanufacturing services — a broad incumbent comparable on customer segment and end-to-end biologics service offering.
  • Distributed Bio (Charles River Laboratories): Distributed Bio's antibody discovery platform (TAb platform, SuperHuman library) is now part of Charles River Laboratories — a broad incumbent offering antibody discovery services as part of a wider CRO portfolio, directly comparable on customer base and offering.
  • WuXi Biologics: WuXi Biologics provides end-to-end biologics discovery, development and manufacturing services including antibody discovery platforms — a broad incumbent that any antibody-discovery services company competes against for biopharma R&D outsourcing budgets.
  • Ablexis / AlivaMab Discovery (AstraZeneca): Ablexis's AlivaMab transgenic mouse antibody platform was acquired by AstraZeneca — a relevant comparable on the transgenic antibody discovery platform side, although now embedded inside a major pharma R&D organization.

Direct peers

  • Alloy Therapeutics: Alloy Therapeutics operates a transgenic antibody discovery platform (ATX-GX™) with AI/ML-driven clone selection and bispecific engineering capabilities — the same product/customer category (biopharma antibody discovery services) deepCDR Biologics addresses, but at significantly greater scale (200+ partners, 20+ partner INDs).
  • AbCellera Biologics: AbCellera is a publicly listed antibody discovery platform using AI/ML and high-throughput single-cell screening to discover therapeutic antibodies — directly comparable technology/market overlap with deepCDR's stated 'cutting-edge' antibody focus.
  • Adimab: Adimab offers a proprietary antibody discovery and optimization platform via partnership-based licensing to pharma and biotech — a direct business-model and offering analogue in the antibody engineering services space.

Emerging players

  • Biolojic Design: Biolojic Design applies AI/ML-driven computational design to antibody engineering — an early-stage, niche AI-native antibody player comparable to the deepCDR positioning around machine-learning-driven CDR engineering.
  • Specifica (AstraZeneca): Specifica built an antibody discovery platform using in vitro display and proprietary libraries before being acquired by AstraZeneca — comparable to deepCDR as an early-stage antibody platform that ultimately required a large-pharma acquirer to commercialize.

Regional players

  • Harbour BioMed: Harbour BioMed operates a transgenic mouse (Harbour Mice®) antibody discovery platform — directly comparable platform technology; though based in Asia/global rather than Switzerland, it targets the same biopharma antibody-discovery licensing customer segment.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights3 records

Customer concentration

deepCDR Biologics social profiles

Digital presence

deepCDR Biologics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

deepCDR Biologics leadership team

Management profile

Number of profiles

Profiles4 records

deepCDR Biologics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

deepCDR Biologics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about deepCDR Biologics

What does deepCDR Biologics do?

deepCDR Biologics is a Basel-based biotechnology company founded in 2019 that provides cutting-edge biotechnology technologies and services with scalable solutions. The company focuses on serving the biologics development needs of pharmaceutical and biotechnology clients with offerings positioned as scalable, technology-driven services.

Is deepCDR Biologics a public or private company?

deepCDR Biologics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was deepCDR Biologics founded?

deepCDR Biologics was founded in 2019. It employs 1 to 10 people.

Where is deepCDR Biologics based?

deepCDR Biologics is headquartered in Basel, Switzerland, in the Europe region.

How does deepCDR Biologics make money?

One revenue line is on record: platform Licensing (ATX-GX™).

Who are deepCDR Biologics's main competitors?

Broad incumbents on record are GenScript ProBio, Distributed Bio (Charles River Laboratories), WuXi Biologics and Ablexis / AlivaMab Discovery (AstraZeneca). Direct peers are Alloy Therapeutics, AbCellera Biologics and Adimab. Emerging players are Biolojic Design and Specifica (AstraZeneca). Harbour BioMed is listed as a regional player.

Does deepCDR Biologics have an API?

No public API is recorded for deepCDR Biologics.

What industry is deepCDR Biologics in?

deepCDR Biologics's product category is Biotechnology Services. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AlloytxAlloy Therapeutics Acquires deepCDR Biologics to Bring Bioinformatics and Machine Learning to its Antibody Discovery OfferingAlloy Therapeutics, a Boston-based biotechnology ecosystem company, announced the acquisition of deepCDR Biologics, a Basel-based developer of deep learning technology for antibody discovery, on December 9, 2021. The acquisition brings deepCDR's machine learning engine and bioinformatics capabilities to Alloy's antibody discovery platform, which serves over 100 global partners, with plans to expand the Basel site and hire additional computational scientists. DeepCDR was founded as a spinoff of ETH Zurich by Associate Professor Sai Reddy and will form Alloy's new Basel operations.Business Wire BlogAlloy Therapeutics Acquires deepCDR Biologics to Bring Bioinformatics and Machine Learning to its Antibody Discovery OfferingAlloy Therapeutics acquired deepCDR Biologics, a Basel-based developer of deep learning technology for antibody discovery. The acquisition adds machine learning-powered antibody repertoire screening and in silico library screening to Alloy's Discovery Services. Alloy will expand the Basel site as a permanent research facility and hire additional computational scientists.BioSpaceAlloy Therapeutics Acquires deepCDR Biologics to Bring Bioinformatics and Machine Learning to its Antibody Discovery OfferingAlloy Therapeutics has acquired deepCDR Biologics, a Basel-based developer of deep learning technology for antibody discovery. The acquisition integrates deepCDR's machine learning capabilities into Alloy's discovery platform to enhance its services for global partners. This move aims to expand Alloy's research facility in Basel and strengthen its AI-driven drug discovery workflows.startupticker.chCombining biologics with deep learning to find new antibodies fasterETH Zurich spin-off deepCDR Biologics won CHF150k from Venture Kick to accelerate antibody drug development. Its deep learning and gene-editing platform can discover thousands of lead candidates in months, up to 10-100 times faster than traditional methods. The company plans to use the funds to expand its team and operational capacity.startupticker.chdeepCDR Biologics AGdeepCDR Biologics AG uses machine learning, gene editing, deep sequencing, and deep learning to generate thousands of optimized antibody lead candidates. Its proprietary mammalian system and workflow aim to produce preclinical-ready candidates faster and cheaper than traditional methods.